Holen Sie sich die Stockscreener-App
17.50
0.17%
-0.03
Handel nachbörslich:
17.85
0.35
+2.00%
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics stock (US67079U1007): clinical pipeline and market reaction under the microscope - AD HOC NEWS
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
NRIX Reiterated by BTIG -- Price Target Maintained at $30 - GuruFocus
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last? - MSN
A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection - simplywall.st
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Nurix Therapeutics' (NRIX) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Nurix Therapeutics : NRIX - 24/7 Wall St.
Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG - Moomoo
Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike - Stock Titan
Nurix (NRIX) director granted stock options on 31,250 common shares - Stock Titan
Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant - Stock Titan
Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director granted 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director awarded 31,250 stock options - Stock Titan
Nurix Therapeutics Shareholders Back Directors and Governance Proposals - TipRanks
Vestal Point (NRIX) discloses 6.5M-share stake, 6.3% of float - Stock Titan
Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay - Stock Titan
Nurix Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares - Stock Titan
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU - Traders Union
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting - Investing News Network
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative? - simplywall.st
Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib - Stock Titan
(NRIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential - AD HOC NEWS
Nurix Therapeutics, Inc.Common stock (NQ: NRIX - FinancialContent
Nurix stock delivers 64% return after Fair Value identified opportunity By Investing.com - Investing.com Australia
Is Nurix Therapeutics (NRIX) Stock’s Premium P/S Multiple Fair After Recent Mixed Share Price Performance - Yahoo Finance
Nurix stock delivers 64% return after Fair Value identified opportunity - Investing.com
How Investors Are Reacting To Nurix Therapeutics (NRIX) Securing EHA Oral Slot For BTK Degrader Data - Yahoo Finance
Nurix Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Vanguard Group Inc. Purchases 1,460,736 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix CEO to speak at two May–June healthcare investor events - Stock Titan
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress - The Manila Times
Nurix Therapeutics Announces Bexobrutideg Oral Presentation - TradingView
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026 - Traders Union
TradingKey - TradingKey
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Move - Sahm
Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushion - AD HOC NEWS
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 - Yahoo Finance
Number of shareholders of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
FMR LLC Boosts Position in Nurix (NRIX) — 5.54M Shares Reported - Stock Titan
Nurix CFO Hans van Houte sells $233k in company stock - Investing.com Canada
Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NRIX) CFO sells 14,055 shares in planned trade - Stock Titan
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
[144] Nurix Therapeutics, Inc. SEC Filing - Stock Titan
Nurix Therapeutics chief legal officer sells $138k in stock By Investing.com - Investing.com India
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):